JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report
- Collection:
- Health Policy and Services Research
- Author(s):
- Atlas, Steven J., author Fox, Grace E., author Agboola, Foluso, author Campbell, Jonathan D., author Pearson, Steven D., author Rind, David M., author Brouwer, Elizabeth, author Carlson, Josh, author Chen, Yilin, (Of University of Washington), author Hansen, Ryan N., author
- Contributor(s):
- Institute for Clinical and Economic Review, issuing body. New England Comparative Effectiveness Public Advisory Council, issuing body.
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, February 27, 2023
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Antibodies, Monoclonal -- therapeutic use Dermatitis, Atopic Janus Kinase Inhibitors -- therapeutic use United States
- Genre(s):
- Technical Report
- Abstract:
- We compared the cost and effectiveness of abrocitinib, baricitinib, tralokinumab and upadacitinib for moderate to severe atopic dermatitis to topical emollients (standard of care) and dupilumab, over a five-year time horizon taking a health system perspective.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (338 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918697384806676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918697384806676